Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SKYEY - SkyePharma PLC -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (30)	5/24/1999 2:25:00 PM
From: Dr. John M. de Castro	Read Replies (2) \| Respond to of 56

SkyePharma Confirms U.S. Launch of DepoCyt(TM) LONDON, May 24 /PRNewswire/ -- SkyePharma PLC (LSE: SKP; Nasdaq: SKYEY)confirms its DepoCyt product, a controlled release injectable form of cytarabine, has been launched in the United States. DepoCyt utilizes SkyePharma's proprietary DepoFoam sustained-release injectable technology and was approved by the US Food and Drug Administration in April 1999. DepoCyt is indicated for lymphomatous meningitis, a complication of cancer. Ian Gowrie-Smith, executive chairman of SkyePharma said, "This is very important news for us and for those suffering from this largely untreated condition." SkyePharma -- one of the world's leading drug delivery companies, develops and manufactures advanced drug delivery solutions. Its technologies include oral controlled-release, injectable and inhalation systems. For company information, visit SkyePharma on the World Wide Web at skyepharma.com.